Open access

411 Novel intratumoral agent, INT230–6 induces cancer cell death, increases tumor infiltrates and results in durable benefit alone or in combination with pembrolizumab in refractory patients
Anthony El-Khoueiry, Jacob Thomas, Anthony Olszanski, Nilofer Azad, Lewis Bender, Ian Walters, Giles Whalen, Diana Hanna, Matthew Ingham, Lilian Siu

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A250; DOI: 10.1136/jitc-2020-SITC2020.0411
414 Enhancing T cell therapy for patients with relapsed/refractory Wilms tumor
Amy Hont, Conrad Cruz, Maja Stanojevic, Robert Ulrey, Madeline Terpilowski, Emily Reynolds, Fahmida Hoq, Maria Fortiz, Haili Lang, Jeffrey Dome, Patrick Hanley, Catherine Bollard, Holly Meany

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A251-A252; DOI: 10.1136/jitc-2020-SITC2020.0414
415 Toripalimab plus nab-paclitaxel and carboplatin as neoadjuvant therapy for patients with esophageal squamous cell carcinoma at clinical stage T2-T4/N0-N2/M0: a single-arm, single-center clinical study
Kunkun Li, Xiao Yang, Wei Luo, Qiang Ma, Yingjian Wang, Yanli Xiong, Xiaolong Zhao, Xianfeng Lu, Tao Bao, Wei Guo, Mengxia Li

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A253; DOI: 10.1136/jitc-2020-SITC2020.0415
416 SQ3370–001 is a multi-center open-label phase I dose-escalation study to test a novel intratumoral and systemic approach to treat advanced solid tumors
Vivek Bhadri, Nam Bui, Alexander Guminski, Jose Mejia Oneto, Ravi Murthy, Kamalesh Sankhala, M Wayne Saville, Sangeetha Srinivasan, Robert Steffner, Vivek Subbiah, Ding Wang, Nathan Yee

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A253-A254; DOI: 10.1136/jitc-2020-SITC2020.0416
417 Design and rationale of a phase 1 study evaluating AMG 256, a novel, targeted, IL-21 receptor agonist and anti-PD-1 antibody, in patients with advanced solid tumors
Gregory Durm, Sophia Frentzas, Erik Rasmussen, Saltanat Najmi, Nooshin Sadraei

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A254; DOI: 10.1136/jitc-2020-SITC2020.0417
418 A phase 1, dose escalation and dose expansion study of SQZ PBMC HPV as monotherapy and in combination with atezolizumab in HLA-A*02+ Patients with HPV16+ recurrent, or metastatic solid tumors
Cathy Eng, Joaquina Baranda, Matthew Taylor, Michael Gordon, Ursula Matulonis, Filip Janku, Martin Kornacker, Asha Kamat, Oliver Rosen, Antonio Jimeno, Cathy Eng

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A254-A255; DOI: 10.1136/jitc-2020-SITC2020.0418
419 Pharmacodynamic biomarkers demonstrate T-cell activation in patients treated with the oral PD-L1 inhibitor INCB086550 in a phase 1 clinical trial
Sarina Piha-Paul, Tara Mitchell, Solmaz Sahebjam, Janice Mehnert, Thomas Karasic, Kevin O’Hayer, Ryan Geschwindt, Susan Spitz, Hao Liu, Johanna Bendell

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A255; DOI: 10.1136/jitc-2020-SITC2020.0419
421 Initial results of a phase 1 trial of RP2, a first in class, enhanced potency, anti-CTLA-4 antibody expressing, oncolytic HSV as single agent and combined with nivolumab in patients with solid tumors
Francesca Aroldi, Joseph Sacco, Kevin Harrington, Anna Olsson-Brown, Pablo Nanclares, Lavita Menezes, Praveen Bommareddy, Suzanne Thomas, Howard Kaufman, Selda Samakoglu, Robert Coffin, Mark Middleton

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A256-A257; DOI: 10.1136/jitc-2020-SITC2020.0421
420 Progression-free survival and biomarker correlates of response with BEMPEG plus NIVO in previously untreated patients with metastatic melanoma: results from the PIVOT-02 study
Adi Diab, Scott Tykodi, Gregory Daniels, Michele Maio, Brendan Curti, Karl Lewis, Sekwon Jang, Ewa Kalinka, Igor Puzanov, Alexander Spira, Daniel Cho, Shanhong Guan, Erika Puente, Ute Hoch, Sue Currie, Tuan Nguyen, Wei Lin, Mary Tagliaferri, Jonathan Zalevsky, Mario Sznol, Michael Hurwitz

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A256; DOI: 10.1136/jitc-2020-SITC2020.0420
422 An open-label, multicenter, phase 1/2 clinical trial of RP1, an enhanced potency oncolytic HSV, combined with nivolumab: updated results from the skin cancer cohorts
Mark Middleton, Francesca Aroldi, Joseph Sacco, Mohammed Milhem, Brendan Curti, Ari VanderWalde MBioeth, Scott Baum, Adel Samson, Anna Pavlick, Jason Chesney, Jiaxin Niu, Terence Rhodes, Tawnya Bowles, Robert Conry, Anna Olsson-Brown, Douglas Earl Laux, Howard Kaufman, Praveen Bommareddy, Alex Deterding, Selda Samakoglu, Robert Coffin, Kevin Harrington

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A257; DOI: 10.1136/jitc-2020-SITC2020.0422

Main menu

Open access

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Open access

Pages